Monday, August 3, 2015

AstraZeneca still being hammered by patent expirations

British-based drugmaker AstraZeneca Plc, which has its regional headquarters in Wilmington, said Thursday morning that revenue and profit declined for 2012 and would do so again in 2013.

AstraZeneca still being hammered by patent expirations

0 comments
AstraZeneca – The world´s fifth-largest pharma was formed in 1993 through a merger. Its market cap is £36.4 billion, and it has a global workforce of 52,700. AstraZeneca operates the AstraZeneca Hope Lodge, which provides free housing to cancer patients being treated in the Philadelphia area.
AstraZeneca – The world's fifth-largest pharma was formed in 1993 through a merger. Its market cap is £36.4 billion, and it has a global workforce of 52,700. AstraZeneca operates the AstraZeneca Hope Lodge, which provides free housing to cancer patients being treated in the Philadelphia area.

British-based drugmaker AstraZeneca Plc, which has its regional headquarters in Wilmington, said Thursday morning that revenue and profit declined for 2012 and would do so again in 2013.

The company said in a statement that it expected sales revenue in 2013 to decline in the "mid-to-high single digits," using constant currency exchange rates. With operating costs likely to be slightly higher, the earnings per share will decline by more than that.

The company did not announce any further layoffs, having reduced its workforce several times in the last couple years.

AstraZeneca released its 2012 fourth quarter and full-year results before the stock market opened Thursday morning in London and chief executive officer Pascal Soriot spoke with reporters on a conference call.

"Our results in 2012 reflect a period of severe patent expiration," Soriot said.

When drugs lose market exclusivity brought on by a patent, generic competitors enter the market with products at much lower costs, resulting in revenue losses for the branded-drug company.

AstraZeneca's full-year revenue fell from $33.59 billion in 2011 to $27.97 billion in 2012, with net profit falling from $10.02 billion to $6.30 billion in the same period.

By the company's math, patent expiration in various parts of the world for four drugs - Seroquel IR, Atacand, Nexium, Merrem - accounted for 85 percent of the revenue decline.

The company's press release, with the numbers, is here.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter